Physical Training Introduction in Lifestyle of Facioscapulohumeral Dystrophy Patients (FSHD1)
|Muscular Dystrophy, Facioscapulohumeral||Other: Physical training Other: Control|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Exercise and Myopathies. Physical Training Introduction in Lifestyle of Facioscapulohumeral Dystrophy Patients: Functional, Tissue and Quality of Life Benefits.|
- maximal oxygen uptake (VO2max) [ Time Frame: Week 24 ]VO2max is meseasured directly by respiratory gas analysis during maximal exercise test on ergocycle
- Questionnaire of quality of life [ Time Frame: Day 0, Week 6, Week 12, Week 18 and Week 24 ]"short form 36 health survey questionnaire" SF36
- Biopsy [ Time Frame: Day 0 and Week 24 ]biopsy of the vastus lateralis muscle
- maximal oxygen uptake (VO2max) [ Time Frame: Week 6, Week 12 and Week 18 ]VO2max is meseasured directly by respiratory gas analysis during maximal exercise test on ergocycle
- Questionnaire of subjective fatigue [ Time Frame: Day 0, Week 6, Week 12, Week 18 and Week 24 ]Fatigue severity scale (FSS)
- nuclear magnetic resonance imaging [ Time Frame: Inclusion ]In Paris centre, a total body NMR imaging will be done with standard T2- and T1-weighted images.
|Study Start Date:||October 2010|
|Study Completion Date:||January 2015|
|Primary Completion Date:||January 2015 (Final data collection date for primary outcome measure)|
Experimental: Physical training
The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. As a result, lower limb muscles will be mainly solicited. These muscles are heterogeneous in terms of deficiency, but this latter is compatible with cycling. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. Over a 2 to 4 weeks initial period, the program will be conducted in the laboratory or at home under the supervision of a coach. Then a systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
Other: Physical training
Physical training during 24 weeks
Our research project aims at establishing a program of physical training that will fulfill the two following conditions: (i) being compatible with the daily professional, social and family activity of the patients so it can be integrated in their life habits and (ii) being intensive enough to induce functional benefits. This experimental work will be based on multi-factorial evaluations, i.e. biological, physiological, functional, and quality of life questionnaires. This work will be based on a collaboration between the Universities of Saint Etienne (L. Féasson), Grenoble (B Wuyam) and Örebro (F Kadi) within the Rhône-Alpes Reference Centre for Rare Neuromuscular Diseases (JC Antoine).
It is accepted that exercise therapy can be recommended for patients with myopathies but long-term training load still has to be determined for each pathology. In the specific context of facioscapulohumeral dystrophy, we aim at associating the scientific evaluation of physical activity benefits and a therapeutic education of patients in order to contribute to recommendations for physicians and physiotherapists. The purpose of this study is to combine an integrated approach with a better understanding of biological process implicated in this physiological treatment strategy.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01116570
|CHU de Grenoble|
|Grenoble, France, 38000|
|CHU de Saint-Etienne|
|Saint-etienne, France, 42055|
|Principal Investigator:||Leonard FEASSON, MD-PhD||CHU de Saint-Etienne|
|Study Chair:||Fawzi KADI, MD-PhD||Orebro University, Sweden|